A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma
Main Authors: | Karthik Ramasamy, Ajay Nooka, Hang Quach, Myo Htut, Rakesh Popat, Michaela Liedtke, Sascha A. Tuchman, Jacob Laubach, Cristina Gasparetto, Asher Chanan-Khan, Mark Hertzberg, Mark deMario, Eveline Nueesch, Evelyne Chesne, Izolda Franjkovic, Katharina Lechner, Martin Kornacker, Hearn Jay Cho |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-09-01
|
Series: | Blood Cancer Journal |
Online Access: | https://doi.org/10.1038/s41408-021-00545-w |
Similar Items
-
Fair bets in sports betting
by: Jansa, Jiří
Published: (2012) -
Lifetime Prediction of Polymers: To Bet, or Not to Bet—Is This the Question?
by: Ignazio Blanco
Published: (2018-08-01) -
Market efficiency of horse-race betting markets with applications to spread betting
by: Twomey, Paul
Published: (2005) -
Halakic (legal) controversies between Bet Hillel, Bet Shammai and Jesus
by: Bradford, Johnnie Edgar
Published: (2015) -
Home bias in sport
betting: Evidence from Czech betting market
by: Rostislav Staněk
Published: (2017-03-01)